Drugs / CAR EBV-VSTs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01430390 | Sep 2011 → Sep 2026 overdue | acute lymphoblastic leukemia | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR EBV-VSTs | “Postinfusion expansion and persistence were limited, and CAR EBV-VSTs demonstrated a unique T-cell phenotype compared with autologous 19-28z CAR T cells.” PMID 39908482 ↗ Apr 2025 |
| Modality | Cell therapy | “allogeneic "off-the-shelf" CAR T-cell product” PMID 39908482 ↗ Apr 2025 |
| Route | Intravenous | “genetically modified T cells will be given intravenously” NCT01430390 ↗ |